Ann: CEO's Presentation AGM 2014, page-28

As I understand it in most countries the public system will be the purchaser of the product. The cost will be too high for most private patients.
Before the public system adds a medicine or device to its list it has to be convinced that the product is more cost effective than current practices. These studies are the evidence that Vitrogrow is more cost effective than current procedures and should be subsidised in part, or full, for clients that need it by the government.